Dr. Perrone's addition to XORTX's Clinical Advisory Board is viewed positively due to his extensive medical and professional experience, especially in ADPKD and kidney disease. His clinical research, trials, and regulatory agency work are anticipated to significantly contribute to XORTX's advanced clinical program and the XRX-OXY-201 registration trial.
$XORTX Therapeutics(XRTX.US)$They now say that they will begin trading tomorrow on 11/14/23 at the 1/9 R/S! Lets see if it get the Pre R/S pop that a lot get? If so? you got to scalp fast! GL
XORTX Therapeutics股票討論區
📊⚡️📊
Update
3 minutes ago, 7:00 AM EST
Via GlobeNewswire
Update
MT Newswires· 3 mins ago
Going to run before weekend
How come cannot sell?
Pre R/S pop possibility?
R/S
暫無評論